Drug Profile
Research programme: herpesvirus inhibitors - Pfizer
Alternative Names: Herpesvirus DNA polymerase inhibitors - Pharmacia; PHA-529311; PHA-568561; PNU 253998; Research programme: herpesvirus inhibitors - PharmaciaLatest Information Update: 27 Sep 2018
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antivirals; Quinolines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cytomegalovirus infections; Epstein-Barr virus infections; Herpes simplex virus infections; Human herpesvirus 6 infections; Human herpesvirus 8 infections; Varicella zoster virus infections
Most Recent Events
- 04 Aug 2009 No development reported - Preclinical for Cytomegalovirus infections in Uganda (PO)
- 04 Aug 2009 No development reported - Preclinical for Epstein-Barr virus infections in USA (PO)
- 04 Aug 2009 No development reported - Preclinical for Herpes simplex virus infections in USA (PO)